natgillin/translations-raw huggingface dataset:
EU ADRs Non-EU ADRs 
Poročila iz EU Poročila, ki niso iz EU
Initial-evaluation applications by type of application, 2004-2006 
Vloge za začetno vrednotenje glede na vrsto uporabe v letih
1.2 x 1066 x 108 cells 
1,2 x 1066 x 108 celic
Bag (ethylene vinyl acetate) 
Vrečka (etilen vinil acetat)
1-3 bags 
1-3 vrečke
Patient specific up to 50 ml max. 
Največ 50 ml za vsakega bolnika posebej
Route of administration 
Stična ovojnina
MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging 
(Izmišljeno) ime Jakost Farmacevtska oblika
21 February 2013 EMA/109958/2013 EMEA/H/C/002350 
21. februar 2013 EMA/109958/2013 EMEA/H/C/002350
The exact mechanisms of action of topiramate are not fully understood. 
Natančen mehanizem delovanja topiramata ni v celoti pojasnjen.
The applicant did propose measures to reduce this risk, but the measures were considered difficult to implement in practice. 
Predlagatelj je predlagal ukrepe za zmanjšanje tega tveganja, vendar je obveljalo, da jih je v praksi težko uveljaviti.
In one of the studies patients were treated for longer and effectiveness measurements were taken after 108 weeks. 
V eni od študij so bili bolniki zdravljeni dalj časa, meritve učinkovitosti pa so bile opravljene po 108 tednih.
Topiramate is also known to be potentially harmful to the unborn baby if taken by pregnant women. 
Za topiramat je znano tudi, da je morebitno škodljiv za nerojenega otroka, če zdravilo jemlje nosečnica.
The effects of Qsiva were first tested in experimental models before being studied in humans. 
Učinki zdravila Qsiva so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The company that applied for authorisation is Vivus BV. 
Vlogo za dovoljenje je predložila družba Vivus BV.
The main measures of effectiveness were the amount of weight loss and the number of patients with at least 5% weight loss after 28 or 56 weeks of treatments. 
Glavni merili učinkovitosti sta bili izgubljena masa in število bolnikov, ki so izgubili vsaj 5 % telesne mase po 28 ali 56 tednih zdravljenja.
It was to be available as modified release capsules. 
Na voljo naj bi bilo v obliki kapsul s prirejenim sproščanjem.
Topiramate is thought to act by increasing the body's energy use, reducing energy efficiency and reducing the patients' appetite for food. 
Za topiramat se predvideva, da deluje tako, da povečuje izrabo energije v telesu, s čimer zmanjšuje energetsko učinkovitost in zmanjša bolnikovo željo po hrani.
Phentermine suppresses appetite by releasing a chemical transmitter called norepinephrine (or noradrenaline) in the hypothalamus, the region of the brain that controls hunger. 
Fentermin zmanjšuje apetit s sproščanjem kemičnega prenašalca, imenovanega norepinefrin (ali noradrenalin) v hipotalamusu, delu možganov, ki nadzira lakoto.
On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Qsiva, intended for the treatment of obesity. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je 18. oktobra 2012 sprejel negativno mnenje in priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Qsiva, namenjenim za zdravljenje debelosti.
After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 21 February 2013. 
Po preučitvi podlage za to zahtevo je CHMP ponovno pregledal prvotno mnenje in dne 21. februarja 2012 potrdil zavrnitev vloge za dovoljenje za promet z zdravilom.
The Committee noted that there was a high probability that, if approved, the medicine would not be used strictly for the intended patients. 
Odbor je opozoril, da obstaja velika verjetnost, da zdravila, v kolikor bi bilo odobreno, bolniki, ki jim je namenjeno, ne bi uporabljali dosledno.
Secondly, there were concerns about the long-term psychiatric effects (depression and anxiety were reported in the studies) and cognitive effects (such as problems with memory and attention) related to the topiramate component of Qsiva. 
Poleg tega so se pojavili zadržki v zvezi z dolgoročnimi psihiatričnimi učinki (v študijah so poročali o depresiji in anksioznosti) ter kognitivnimi učinki (kot so težave s spominom in pozornostjo), povezanimi s sestavino topiramat zdravila Qsiva.
Therefore, the CHMP concluded that the benefits of Qsiva did not outweigh its risks and recommended that it be refused marketing authorisation. 
Odbor CHMP je zato zaključil, da koristi zdravila Qsiva niso večje od z njim povezanih tveganj, in priporočil, da se zanj zavrne dovoljenje za promet.
What is Qsiva? 
Kaj je zdravilo Qsiva?
The company informed the CHMP that that there are no consequences for patients involved in clinical trials. 
Družba je obvestila odbor CHMP, da zavrnitev nima nobenih posledic za bolnike, ki sodelujejo v kliničnih preskušanjih.
Two of the studies specifically included patients with weight-related health problems, including diabetes, high blood pressure, and abnormal fat and sugar levels in the blood. 
Dve od študij sta specifično vključili bolnike z zdravstvenimi težavami, povezanimi s telesno maso, vključno s sladkorno boleznijo, visokim krvnim tlakom in nenormalnimi ravnmi maščobe ter sladkorja v krvi.
The CHMP noted that the main studies showed clinically relevant weight loss following treatment with Qsiva but had concerns about the medicine's long-term effects on the heart and blood vessels, particularly due to the effects of phentermine, which is known to increase the heart rate but whose long-term effects are not clear. 
Odbor CHMP je opozoril, da so glavne študije dokazale klinično pomembno izgubo telesne mase po zdravljenju z zdravilom Qsiva, vendar je izrazil zadržke v zvezi z dolgoročnimi učinki zdravila na srce in krvne žile, še posebej zaradi učinkov fentermina, za katerega je znano, da povečuje srčni utrip, njegovi dolgoročni učinki pa niso jasni.
Qsiva is a medicine that contains the active substances phentermine and topiramate. 
Qsiva je zdravilo, ki vsebuje zdravilni učinkovini fentermin in topiramat.
The two active substances in Qsiva are appetite suppressants. 
Obe zdravilni učinkovini v zdravilu Qsiva sta sredstvi za zmanjševanje apetita.
Qsiva was expected to be used to treat severely obese patients (BMI ≥ 35 kg/m2), or patients with obesity (BMI ≥ 30 kg/m2) who have weight-related health problems, such as high blood pressure, type 2 diabetes or abnormal levels of fat in the blood. 
Zdravilo Qsiva naj bi se uporabljalo za zdravljenje bolnikov z izrazito čezmerno telesno maso (ITM ≥ 35 kg/m2) in bolnikov s čezmerno telesno maso (BMI ≥ 30 kg/m2), ki imajo zdravstvene težave, povezane s telesno maso, npr. visok krvni tlak, sladkorno bolezen tipa 2 ali nenormalne ravni maščob v krvi.
Four main studies involving a total of approximately 4,000 obese or overweight patients were conducted that compared Qsiva treatment with placebo (a dummy treatment) and with phentermine or topiramate treatments given alone. 
Opravljene so bile štiri glavne študije, ki so skupno vključevale približno 4.000 debelih oz. pretežkih bolnikov, za primerjavo zdravljenja z zdravilom Qsiva in placeba (zdravila brez zdravilne učinkovine) ter monoterapij s fenterminom in topiramatom.
What was Qsiva expected to be used for? 
Za kaj naj bi se zdravilo Qsiva uporabljalo?
How is Qsiva expected to work? 
Kako naj bi zdravilo Qsiva delovalo?
The full EPAR for Zarzio can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zarzio je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Zarzio? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zarzio?
The European Commission granted a marketing authorisation valid throughout the EU for Zarzio on 06 February 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Zarzio, veljavno po vsej Evropski uniji, izdala 6. februarja 2009.
This means that Zarzio is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine'). 
To pomeni, da je podobno biološkemu zdravilu, ki je že odobreno v Evropski uniji (EU) in vsebuje enako zdravilno učinkovino (imenovano tudi „referenčno zdravilo“).
This is a summary of the European public assessment report (EPAR) for Zarzio. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zarzio.
The most common side effect with Zarzio (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). 
Najpogostejši neželeni učinki zdravila Zarzio (opaženi pri več kot 1 bolniku od 10) so mišično-skeletne bolečine (bolečine v mišicah in kosteh).
Four studies looked at the levels of neutrophils in the blood in a total of 146 healthy volunteers who received Zarzio or Neupogen. 
S štirimi študijami so raziskovali ravni nevtrofilcev v krvi pri skupaj 146 zdravih prostovoljcih, ki so prejeli zdravili Zarzio ali Neupogen.
Filgrastim is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce filgrastim. 
Filgrastim se izdeluje z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri se v bakterijo vstavi gen (DNK), s katerim lahko tvori filgrastim.
For more information about treatment with Zarzio, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zarzio preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Zarzio, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G CSF). 
Zdravilna učinkovina v zdravilu Zarzio, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije spodbujajoči faktor (G CSF).
Zarzio is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately. 
Zdravilo Zarzio se ponavadi daje v specializiranih centrih za zdravljenje, čeprav si lahko bolniki, ki prejemajo injekcijo v podkožje in so bili ustrezno usposobljeni, cepivo vbrizgajo sami.
What benefit has Zarzio shown during the studies? 
Kakšne koristi je zdravilo Zarzio izkazalo med študijami?
Zarzio is used to stimulate the production of white blood cells in the following situations: 
Zdravilo Zarzio se uporablja za stimulacijo tvorbe belih krvničk v naslednjih primerih:
Other information about Zarzio 
Druge informacije o zdravilu Zarzio
A risk management plan has been developed to ensure that Zarzio is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Zarzio je bil pripravljen načrt obvladovanja tveganj.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zarzio. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Zarzio can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow. 
Zdravilo Zarzio lahko uporabljajo tudi darovalci krvnih matičnih celic, namenjenih za presaditev, da se olajša sproščanje teh celic iz kostnega mozga.
Zarzio and Neupogen brought about similar increases in blood neutrophil counts in healthy volunteers over the course of the studies. 
Zdravili Zarzio in Neupogen sta med študijami povzročili približno enako povečanje števila nevtrofilcev v krvi pri zdravih prostovoljcih.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zarzio, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The Committee recommended that Zarzio be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Zarzio izda dovoljenje za promet.
What is the risk associated with Zarzio? 
Kakšna tveganja so povezana z zdravilom Zarzio?
Why has Zarzio been approved? 
Zakaj je bilo zdravilo Zarzio odobreno?
Zarzio was studied to show that it is comparable to the reference medicine, Neupogen. 
Zdravilo Zarzio so proučevali, da bi dokazali, da je primerljivo z referenčnim zdravilom Neupogen.
The CHMP decided that, in accordance with EU requirements, Zarzio has been shown to have a comparable quality, safety and efficacy profile to Neupogen. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Zarzio po kakovosti, varnosti in učinkovitosti primerljivo z zdravilom Neupogen.
Other side effects may be seen in more than 1 patient in 10, depending on the condition that Zarzio is being used for. 
Drugi neželeni učinki se lahko pojavijo pri več kot 1 bolniku od 10, odvisno od bolezni, ki se zdravi z zdravilom Zarzio.
This was considered sufficient to demonstrate that the benefits of Zarzio are comparable to those of the reference medicine. 
To je štelo kot zadosten dokaz, da so koristi zdravila Zarzio primerljive s tistimi pri referenčnem zdravilu.
Zarzio is a ‘biosimilar' medicine. 
Zarzio je podobno biološko zdravilo.
Zarzio is a solution for injection or infusion (drip into a vein) in a pre-filled syringe. 
Zdravilo Zarzio je raztopina za injiciranje ali infundiranje (dajanje v veno) v napolnjeni injekcijski brizgi.
The reference medicine for Zarzio is Neupogen. 
Referenčno zdravilo za Zarzio je zdravilo Neupogen.
What is Zarzio used for? 
Za kaj se zdravilo Zarzio uporablja?
How has Zarzio been studied? 
Kako je bilo zdravilo Zarzio raziskano?
Zarzio is given by injection under the skin or infusion into a vein. 
Zdravilo Zarzio se injicira v podkožje ali infundira v veno.
How does Zarzio work? 
Kako zdravilo Zarzio deluje?
How is Zarzio used? 
Kako se zdravilo Zarzio uporablja?
What is Zarzio? 
Kaj je zdravilo Zarzio?
It is available as capsules (5, 20, 100, 140, 180 and 250 mg). 
Na voljo je v obliki kapsul (5-, 20- , 100-, 140-, 180- in 250-miligramskih).
The full EPAR for Temomedac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Temomedac je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What are the benefits and risks of Temomedac? 
Kakšne so koristi in tveganja, povezani z zdravilom Temomedac?
The European Commission granted a marketing authorisation valid throughout the EU for Temomedac on 25 January 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Temomedac, veljavno po vsej Evropski uniji, izdala dne 25. januarja 2010.
Temomedac is used first with radiotherapy and then on its own; 
Zdravilo Temomedac se najprej uporabi skupaj z radioterapijo, nato pa samostojno;
This means that Temomedac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Temodal.
This document is a summary of the European Public Assessment Report (EPAR) for Temomedac. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Temomedac.
Temomedac capsules should be taken whole without food. 
Kapsule zdravila Temomedac je treba zaužiti cele, brez hrane.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temomedac. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Temomedac: 
Druge informacije o zdravilu Temomedac:
Treatment with Temomedac should be prescribed by a doctor with experience in the treatment of brain tumours. 
Zdravljenje z zdravilom Temomedac mora predpisati zdravnik, ki ima izkušnje z zdravljenjem možganskih tumorjev.
Temomedac is used to treat malignant glioma (brain tumours) in the following groups of patients: 
Zdravilo Temomedac se uporablja za zdravljenje malignih gliomov (možganskih tumorjev) pri naslednjih skupinah bolnikov:
The Committee recommended that Temomedac be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Temomedac izda dovoljenje za promet.
Because Temomedac is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine. 
Ker je zdravilo Temomedac generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Temomedac is a ‘generic medicine'. 
Zdravilo Temomedac je „generično zdravilo“.
For more information about treatment with Temomedac, read the Package Leaflet (also part of the EPAR). 
Za več informacij o zdravljenju z zdravilom Temomedac preberite navodilo za uporabo (ki je prav tako del EPAR).
The CHMP concluded that, in accordance with EU requirements, Temomedac has been shown to have comparable quality and to be bioequivalent to Temodal. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Temomedac primerljivo raven kakovosti kot zdravilo Temodal ter da mu je biološko enakovredno.
Because Temomedac is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. 
Ker je zdravilo Temomedac generično zdravilo, so bile študije na ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Temodal.
Temomedac is a cancer medicine that contains the active substance temozolomide. 
Temomedac je zdravilo proti raku, ki vsebuje zdravilno učinkovino temozolomid.
The active substance in Temomedac, temozolomide, belongs to a group of cancer medicines called alkylating agents. 
Zdravilna učinkovina zdravila Temomedac, temozolomid, spada v skupino zdravil proti raku, imenovanih alkilirajoči citostatiki.
Temomedac is used on its own in these patients. 
Pri teh bolnikih se zdravilo Temomedac uporablja samostojno.
Why has Temomedac been approved? 
Zakaj je bilo zdravilo Temomedac odobreno?
Patients may also need to take medicines to prevent vomiting before taking Temomedac. 
Preden bolnik vzame zdravilo Temomedac, bo morda potreboval tudi zdravilo za preprečevanje bruhanja.
The dose of Temomedac depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day. 
Odmerek zdravila Temomedac je odvisen od telesne površine (izračunane glede na telesno višino in maso bolnika) in znaša od 75 do 200 mg na kvadratni meter enkrat na dan. Odmerek in število odmerkov sta odvisna od vrste zdravljenega tumorja, od tega, ali je bil bolnik že zdravljen, od tega, ali se zdravilo Temomedac uporablja samostojno ali skupaj z drugimi zdravljenji, in od tega, kako se bolnik odziva na zdravljenje.
What is Temomedac used for? 
Za kaj se zdravilo Temomedac uporablja?
How is Temomedac used? 
Kako se zdravilo Temomedac uporablja?
How has Temomedac been studied? 
Kako je bilo zdravilo Temomedac raziskano?
How does Temomedac work? 
Kako zdravilo Temomedac deluje?
What is Temomedac? 
Kaj je zdravilo Temomedac?
1 vial + 1 filter needle 
1 viala + 1 igla s filtrom
Solution for injection Intravitreal use pre-filled syringe 
1 viala raztopina za injiciranje intravitrealna uporaba napolnjena injekcijska brizga
1 vial 
Jakost
Packaging Package size unit dose blister (PVC/PVDC/alu) 
Pakiranje Velikost pakiranja pretisni omot za enkratni odmerek (PVC/PVDC/alu)
EMEA Number 
EMEA številka
100 x 1 tablet l t o r 
100 x 1 tableta o ā
It has no relevant use in patients under 18 years of age. 
Ni primeren za uporabo pri bolnikih, mlajših od 18 let.
2 February 2016 EMA/822538/2015 
februar 2016 EMA/822538/2015
Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba 
Epilobium angustifolium L. in/ali Epilobium parviflorum Schreb., herba
Willow herb EMA/822538/2015 
Zel vrbovca EMA/822538/2015
Results from laboratory studies indicate that willow herb may have an effect on the growth of prostate cells as well as anti-inflammatory and pain-relieving activity. 
Rezultati laboratorijskih preskusov kažejo, da ima zel vrbovca morda učinek na rast celic prostate ter protivnetno in protibolečinsko delovanje.
However, firm conclusions could not be drawn and the HMPC conclusions on the use of willow herb are based on their long-standing use. 
Vendar trdnih zaključkov ni bilo mogoče sprejeti in zaključki odbora HMPC v zvezi z uporabo zeli vrbovca zato temeljijo na njegovi dolgotrajni uporabi.
This summary is not intended to provide practical advice on how to use medicines containing willow herb. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel vrbovca.
Willow herb preparations are obtained by drying and comminuting (reducing into tiny pieces) the aerial parts of the plant. 
Pripravki z zeljo vrbovca se pridobivajo s sušenjem in drobljenjem (zmanjševanjem na majhne delce) nadzemnih delov rastline.
Willow herb should only be used after serious conditions have been excluded by a medical doctor. 
Zel vrbovca se sme uporabljati šele, ko zdravnik izključi resnejša bolezenska stanja.
The HMPC noted the lack of clinical studies with willow herb. 
Odbor HMPC je ugotovil pomanjkanje kliničnih študij z zeljo vrbovca.
BPH is a non-cancerous increase in size of the prostate gland which surrounds the urethra, the tube that carries urine from the bladder out of the body. 
BHP je nerakavo povečanje žleze prostate, ki obdaja sečevod, to je cev, ki odvaja urin iz sečnega mehurja ven iz telesa.
Further information on the risks associated with willow herb medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo zel vrbovca, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
The HMPC concluded that, on the basis of its long-standing use, willow herb can be used by patients with benign prostatic hyperplasia (BPH) for the relief of lower urinary tract symptoms such as difficulty starting urination or a frequent need to urinate. 
Odbor HMPC je na podlagi dolgotrajne uporabe zaključil, da lahko zel vrbovca uporabljajo bolniki z benigno hiperplazijo prostate (BHP) za lajšanje simptomov v spodnjih sečilih, kot sta težaven začetek uriniranja in pogosto uriniranje.
Herbal medicines containing willow herb are usually available as herbal tea to be drunk. 
Zdravila rastlinskega izvora, ki vsebujejo zel vrbovca, so navadno na voljo kot zdravilni čaj, ki se popije.